pharma · Lupus Nephritis · Generalized Myasthenia Gravis · AUPH
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 1196 Hwy 3 South, Northfield, MN 55057, US
- Founded
- 2007
- Employees
- 81
- Programs
- 14
- Drugs
- 10
- Patents
- 7
Aurinia Pharmaceuticals patents
7 pharmaceutical patents indexed for Aurinia Pharmaceuticals. 0 expire within 24 months.
Aurinia Pharmaceuticals has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11622991
Protocol for treatment of lupus nephritis
granted -
US 10973871
Ophthalmic compositions
granted -
US 10472394
Cyclosporine analogue mixtures and their use as immunomodulating agents
granted -
US 10286036
Protocol for treatment of lupus nephritis
granted -
US 10265375
Ophthalmic compositions
granted -
US 9765119
Cyclosporine analogue mixtures and their use as immunomodulating agents
granted -
US 9017725
Topical drug delivery systems for ophthalmic use
granted
Frequently asked questions
How many patents does Aurinia Pharmaceuticals have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Aurinia Pharmaceuticals patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.